The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data* Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Fluorodeoxyglucose F18
  • Hodgkin Disease
  • Lymphoma, Large B-Cell, Diffuse
  • Radiopharmaceuticals

publication date

  • June 2, 2017

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1080/10428194.2017.1323270

PubMed ID

  • 28573908

Additional Document Info

start page

  • 1

end page

  • 3